TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Patient Centered Results for Uterine Fibroids

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of UF by imaging or pathology report within 2 years of enrollment initiation.~* Menstrual period within 12 months~Exclusion Criteria:~* Post-menopausal~* Men~* 55 years old or older

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 54 Years
- Healthy Volunteers: f

Study Arms:
- Medical (Type: None): Patients who receive medical therapy only for treatment of their uterine fibroids
- Procedure (Type: None): Patients who have a hysterectomy, myomectomy, uterine arterial embolization, endometrial ablation, radiofrequency ablation, or magnetic resonance guided focused ultrasound to treat their UF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Canakinumab in Schnitzler Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of Schnitzler syndrome as per criteria (ref 1).~* Patients that have been / are treated with Anakinra must have demonstrated a partial or complete clinical response with an associated normalization of their biomarkers of inflammation (CRP).~* Male and female patients at least 18 years of age at the time of the screening visit.~* Patient's informed consent.~* Negative QuantiFERON test or negative Purified Protein Derivative (PPD) test (\< 5 mm induration) at screening or within 1 month prior to the screening visit, according to the national guidelines. Patients with a positive PPD test (≥ 5 mm induration) at screening may be enrolled only if they have either a negative chest x-ray or a negative QuantiFERON test (QFT-TB G In-Tube).~* Adequate contraception in premenopausal females~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* History of being immunocompromised, including a positive HIV at screening (ELISA and Western blot).~* Serologic evidence of hepatitis B or C infection~* Live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose~* History of significant medical conditions, which in the Investigator's opinion would exclude the patient from participating in this trial~* History of recurrent and/or evidence of active bacterial, fungal, or viral infection(s)~* Use of the following therapies:~  * Anakinra within 24 hours prior to Baseline visit XML File Identifier : tl8ybe8lI1o6DeawQocCBa8TF/w=~ * Corticosteroids (oral prednisone (or equivalent)) \> 1.0 mg/kg/day (or greater than the maximum of 60 mg/day for children over 60 kg) within 3 days prior to the Baseline visit~ * Intra-articular, peri-articular or intramuscular corticosteroid injections within 4 weeks prior to the Baseline visit~ * Any other investigational biologics within 8 weeks prior to the Baseline visit~ * Any other investigational drugs, other than investigational biologic treatment, within 30 days (or 3 months for investigational monoclonal antibodies) or 5 half-lives prior to the Baseline visit, whichever is longer~* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): A 6-month open-label, single treatment arm study of canakinumab 150 or 300 mg (in case of insufficient response to 150 mg) subcutaneous injection once per month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Grade 6 or 7 student at a participating school~* Written parent or guardian consent to participate~* Self-identifies as African American or black~Exclusion Criteria:~- Those not meeting inclusion criteria were excluded.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Abstinence-only (Type: EXPERIMENTAL): Participants will receive the abstinence-only HIV/STD risk-reduction intervention.
- Safer-sex only (Type: EXPERIMENTAL): Participants will receive the safer-sex-only HIV/STD risk-reduction intervention.
- Comprehensive-long (Type: EXPERIMENTAL): Participants will receive the 12-h long comprehensive HIV/STD risk-reduction intervention.
- Comprehensive-short (Type: EXPERIMENTAL): Participants will receive the 8-h short comprehensive HIV/STD risk-reduction intervention.
- Health-promotion control (Type: ACTIVE_COMPARATOR): Participants will receive the health promotion control intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 1 to ≤ 18 years at enrollment. Patient should be able to swallow tablet form. Weight should be ≥ 12kg.~* Diagnosis of persistent (3-\<12 months duration) or chronic cases (≥12 months duration) with day 1 platelet count ≤ 20x10\^9.~* Patients have a bleeding score grade 3 for skin and/or grade 2 or higher for mucosal domains and/or higher than grade 1 for organ domain at the baseline visit or the worst bleeding incident episode in the patient's medical reports in the last 3 months prior screening, using ITP-BAT (v1.0) score.~* Normal Kidney function tests and liver function tests.~Exclusion Criteria:~* Acute thrombocytopenic purpura patients or Other causes of thrombocytopenia. Patients with Evans syndrome~* Hypertension, cardiovascular disease, diabetes, hepatitis C virus (HCV), HIV, hepatitis B surface antigen(HBsAg) seropositive status.~* Baseline bone marrow biopsy with evident fibrosis (reticulin stain grade 2 or more)~* Patients who have previously received eltrombopag.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- group 1 Eltrombopag arm (Type: EXPERIMENTAL): Group 1 (eltrombopag arm n=20 patients): Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy. patients will receive a total daily dose of eltrombopag of (25-50mg/d). Dose adjustments may be made based on platelets count with an increment of 25mg once per day at 2 weeks intervals (Maximum dose: 75 mg orally once a day).~Patients, who responded poorly to eltrombopag in 6 months or developed adverse effects, were asked to discontinue the medication. Those who responded were followed for further 6 month period.
- group 2 conventional Treatment (Type: ACTIVE_COMPARATOR): Group 2 (n=20 patients) Patients who are currently receiving other lines of treatment (steroids, IVIG, azathioprine, and rituximab).~patients will continue on the conventional line of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia by two senior psychiatrists~* Between 18 and 60 years and Han Chinese~Exclusion Criteria:~* A Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV Axis I diagnosis other than schizophrenia~* Documented disease of physical diseases including, but not limited to seizure, epilepsy, aneurysm brain tumor, and stroke, dementia, parkinson's disease, Huntington's disease, multiple sclerosis~* Acute, unstable and/or significant and untreated medical illness (e.g., infection, unstable diabetes, uncontrolled hypertension)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- olanzapine-sertraline combination (Type: EXPERIMENTAL): the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
- only olanzapine (Type: PLACEBO_COMPARATOR): the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
- risperidone-sertraline combination (Type: EXPERIMENTAL): the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
- only risperidone (Type: PLACEBO_COMPARATOR): the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
- paliperidone-sertraline combination (Type: EXPERIMENTAL): the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
- only paliperidone (Type: PLACEBO_COMPARATOR): the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
- ziprasidone-sertraline combination (Type: EXPERIMENTAL): the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
- only ziprasidone (Type: PLACEBO_COMPARATOR): the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 1 or Type 2 diabetes mellitus must have a documented clinical diagnosis of painful diabetic peripheral neuropathy with symptoms and signs for at least 6 months, and pain present at the time of screening~* The investigator considers the patient's blood glucose to be controlled by diet, or hypoglycemics, or insulin for at least 3 months prior to enrolling in the study (this control should be documented by figures of glycated hemoglobin \[HbA1c\] no greater than 11% at screening)~* Patients have been taking analgesic medications for the condition for at least 3 months prior to screening (patients taking opioid analgesics must be dissatisfied with current treatment, and patients taking non-opioid analgesics must be dissatisfied with current analgesia)~* Patients currently requiring opioid treatment must be taking daily doses of an opioid-based analgesic equivalent to \<=160 mg of oral morphine~Exclusion Criteria:~* No significant pulmonary, gastrointestinal, endocrine, metabolic (except diabetes mellitus), neurological, psychiatric disorders (resulting in disorientation, memory impairment or inability to report accurately as in schizophrenia, Alzheimer's disease), or any other clinically significant disease that in the Investigator's opinion may affect efficacy or safety assessments or may compromise patient's safety during trial participation~* no history of moderate to severe hepatic impairment such as chronic hepatitis B or C, presence of active hepatitis B or C within the last 3 months or impaired hepatic function with ALT or AST greater than 3-fold ULN~* No patients with severely impaired renal function~* No laboratory values above or below limits of normal unless considered not clinically relevant by the Investigator~* No significant cardiac disease (e.g., unstable angina pectoris, angina pectoris Canadian Cardiovascular Society (CCS) class III-IV, acute myocardial infarction within the last 3 months, cardiac insufficiency New York Heart Association (NYHA) class III-IV) or significant vascular disease (e.g., peripheral arterial occlusive disease (PAOD) Fontaine class IIb-IV)~* no life-long history of seizure disorders or epilepsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo matching placebo twice daily for 12 weeks
- CG5503 (Type: EXPERIMENTAL): CG5503 100, 150, 200, 250mg twice daily given for up to 15 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PPAR-COMBO With Sulfonylurea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes, HbA1c \> 7.0% and \< 10.0%, mean serum triglyceride \< 600 mg/dL, body mass index \< 41 kg/m2, fasting c-peptide . 1.5 ng/mL.~Exclusion Criteria:~* History of MI (myocardial infarction), coronary angioplasty or bypass graft(s), valvular disease or repair, unstable angina pectoris, transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months, congestive heart failure (NYHA Class III and IV, uncontrolled hypertension, history or renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients diagnosed as schizophrenia by the Diagnostic and Statistical Manual of Mental Disorders.~* Age between 18-45 years~* Patients who started atypical antipsychotic drug treatment or patients who switched from the previous conventional or atypical antipsychotic treatment to another atypical antipsychotic drug treatment by the decision of their physicians.~Exclusion Criteria:~* Patients who are pregnant or considering pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Atypical Antispychotics (or second generation antipsychotics) (Type: None): Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must sign an Institutional Review Board (IRB) approved written informed consent for this study.~2. Male and female 18 years of age and older.~3. Participants must have clinical diagnosis of moderate to severe rosacea.~4. Have a minimum total of 15 and a maximum of 70 total inflammatory lesions (papules and/or pustules) including those present on the nose.~5. Have 2 nodules or less.~Exclusion Criteria:~1. Females, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation or were found to have positive pregnancy test at Baseline or screening visits.~2. Presence of more than 2 facial nodules or any nodule greater than 1 centimeter (cm).~3. Current or past ocular rosacea (for example, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S5G4T-1 (Type: EXPERIMENTAL): Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
- S5G4T-2 Vehicle Cream (Type: PLACEBO_COMPARATOR): Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Text-Message-Based Depression Prevention for High-Risk Youth in the ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking~* presenting to the emergency department for routine care~* reporting past-year physical violence (using a modified version of The Revised Conflict Tactics Scales (CTS)) and current mild-to-moderate depressive symptoms (using Patient Health Questionnaire (PHQ)-9), as identified on a brief screen administered in the ED~* accompanied by a consentable parent~* own or have access to a text-message-capable mobile phone~Exclusion Criteria:~* medically/physically unable to assent~* chief complaint of suicidal ideation, psychosis, or child abuse~* in police custody~* severe depressive symptoms

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- iDOVE Intervention (ED+text) (Type: EXPERIMENTAL): 1. In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~2. Eight-week longitudinal tailored CBT-based text-message program
- Control (EUC) (Type: PLACEBO_COMPARATOR): 1. In-ED brief session, discussing home safety \& nutrition~2. Eight-week longitudinal home safety \& nutrition text-message program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ease of Use of New Blood Glucose Meter With In-built Insulin Calculator at Home Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with Type 1 or 2 diabetes on a bolus regime (U100 insulin), one or more bolus injections per day for at least 6 months;~* Age 18 yrs and above;~* Regularly testing SMBG 3 or more times per day;~* Willingness to test at least 4 times per day.~Exclusion Criteria:~* Know to require a bolus injection of more than 50U in a single dose;~* Has previously used either the InsuLinx or assigned comparison meter;~* Participated in structured diabetes management training in the last 6 months~* Is currently on an insulin pump;~* Has concomitant disease that, in the Investigator's opinion, may compromise patient safety;~* Is participating in another study of a glucose monitoring device or drug that could affect glucose measurements or glucose management;~* Female subject who is pregnant or planning to become pregnant during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADC, Then Comparator, Then ADC With Calculator (Type: EXPERIMENTAL): Subject used the ADC blood glucose meter for 7 days with the insulin calculator not activated, followed by a comparator blood glucose meter for 7 days. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
- Comparator, Then ADC, Then ADC With Calculator (Type: EXPERIMENTAL): Subject used a comparator blood glucose meter for 7 days, followed by the ADC blood glucose meter for 7 days, with the insulin calculator not activated. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete